Saudi Journal of Gastroenterology

ORIGINAL ARTICLE
Year
: 2007  |  Volume : 13  |  Issue : 1  |  Page : 21--24

Radiological response in Saudi patients undergoing transarterial chemoembolization for hepatocellular carcinoma


Turki Al Fuhaid1, Majid Al Madi2, Huda Al Abdul Kareem3, Manal Al Dukhayil3, Ayman A Abdo3,  
1 Department of Radiology, King Khalid University Hospital, Riyadh, Saudi Arabia
2 Gastroenterology Unit, Department of Medicine, McGill University, Montreal, Canada
3 Department of Medicine, King Khalid University Hospital, Riyadh, Saudi Arabia

Correspondence Address:
Ayman A Abdo
College of Medicine, P.O. Box 2925 (59), Riyadh 11461
Saudi Arabia

Abstract

Background: Hepatocellular carcinoma (HCC) is the second commonest cancer affecting males and the eighth most common one affecting females in Saudi Arabia. Transarterial chemoembolization (TACE) is currently considered the first line therapy for multifocal HCC in selected patients. Objective: To evaluate HCC response to TACE based on triphasic computerized tomography (CT) of the liver obtained 6 weeks after the procedure. Materials and Methods: A retrospective chart review of 15 patients who underwent TACE in King Khalid University Hospital for unresectable HCC. Patients were staged according to the Child-Pugh, Okuda, and CLIP scoring systems. The first triphasic CT of the liver after TACE was evaluated for Lipiodol uptake and interval change in tumor burden. Results: The mean age was 63 years (40-82), 10 were males (66.7%), and five were females. About 11 patients had cirrhosis (73.3%). Eight patients (53.3%) were Child-Pugh class A while seven (46.7%) were Child-Pugh class B. One patient died and two were lost to follow up. Four patients had a complete response to TACE (26.7%), two had a partial response (13.3%), five showed no change (33.3%) and none showed progression of disease. Tumoral Lipiodol uptake in five patients was >75% (33.3%), in two 75-50% (13.3%) while in four patients it was <50% (26.7%). Conclusion: Our results show that TACE is an effective method of reducing the tumor burden in selected patients with unresectable HCC.



How to cite this article:
Al Fuhaid T, Al Madi M, Al Abdul Kareem H, Al Dukhayil M, Abdo AA. Radiological response in Saudi patients undergoing transarterial chemoembolization for hepatocellular carcinoma.Saudi J Gastroenterol 2007;13:21-24


How to cite this URL:
Al Fuhaid T, Al Madi M, Al Abdul Kareem H, Al Dukhayil M, Abdo AA. Radiological response in Saudi patients undergoing transarterial chemoembolization for hepatocellular carcinoma. Saudi J Gastroenterol [serial online] 2007 [cited 2021 Jan 27 ];13:21-24
Available from: https://www.saudijgastro.com/text.asp?2007/13/1/21/30461


Full Text

Hepatocellular carcinoma (HCC) is the commonest primary malignancy of the liver.[1] World wide it ranks the fifth most common cancer and the third most common cause of cancer related death. HCC is a significant cause of mortality and morbidity in Saudi Arabia, constituting 6.1% of all newly diagnosed cancers and 87.6% of all liver cancers. According to the most recent publication of the National Cancer Registry of Saudi Arabia, HCC is the second commonest cancer affecting males and the eighth commonest cancer in females.[2]

Patients' management with HCC varies from liver transplantation to palliation. Transarterial chemoembolization (TACE) is a technique that has emerged as a modality of treating patients with unresectable multifocal HCC without vascular invasion or metastasis.

In this study, we describe our initial experience with 15 patients who underwent TACE for HCC with a special emphasis on tumor response based on the initial triphasic CT of the liver.

 Materials and Methods



The charts of all patients who had TACE for HCC from November 2003 to November 2005 were reviewed. These patients were diagnosed with HCC either at King Khalid University Hospital, Riyadh, Saudi Arabia or referred with the diagnosis from other hospitals. The diagnosis was based on the recommendations of the European Association for the Study of Liver in which the diagnosis of HCC in cirrhotic patients would be made if the patient had a lesion more than 2 cm in size with arterial hypervascularization on two imaging techniques (ultra sound, spiral CT, MRI, and angiography) or had a lesion more than 2 cm in size with arterial hypervascularization and an AFP level more than 400 ng/mL.[3]

Only patients with Child-Pugh class A or B with no evidence of extrahepatic spread or portal vein thrombosis were considered for TACE. Patients were classified according to the Okuda[4] and Cancer of the Liver Italian Program (CLIP)[5] staging systems.

All patients had triphasic CT of the liver to evaluate tumor burden, arterial anatomy, and portal vein (PV) patency prior to the procedure. TACE procedure was performed within 6 weeks from initial diagnostic CT scan. Each patient had full explanation of the procedure and signed a consent form.

All patients were admitted to the hospital one day prior to the procedure. PV patency was confirmed with Doppler prior to procedure. Based on arterial anatomy, revealed by the CT, the tumor-feeding artery (whether it arises from celiac or superior mesenteric artery) was then catheterized with subsequent injection of an emulsion of 10 mL of Lipiodol Ultrafluid with 5 mL of Omnipaque 300 mixed with Doxorubicin. Doxorubicin dose given was 75 mg/m 2 if bilirubin was 2 if bilirubin was 25.5-51.3 mmol/L and 25 mg/m 2 if bilirubin >51.3 mmol/L as per the Barcelona protocol.[6] Then the feeding artery was embolized with poly vinyl alcohol. Its size and amount varies with the size of the feeding vessel till stagnation of blood flow was achieved. Patients are kept in the hospital for observation for 5 days. After 6 weeks, triphasic CT of the liver was obtained to assess treatment response. This was based on Lipiodol uptake and the interval change in tumor burden. Lipiodol uptake was classified as >75%, 50-75% or 75% (33.3%), two showed an uptake of 75-50% (13.3%) and five showed an uptake of the survival was 57% at 1 year, 31% at 2 years, and 26% at 3 years in the TACE arm as compared to 32% at 1 year, 11% at 2 years, and 3% at 3 years in the control group. Similarly in a meta-analysis performed by Llovet and colleagues,[10] TACE reduced the two year mortality from 41% in the control group vs. 27% in the TACE group. A possible explanation for the favorable results of the last two trials is the selectivity of patients with less advanced liver disease and smaller tumors compared to previous trials. In addition, in the last two trials patients received multiple sessions of TACE regardless of the initial response.

The survival benefit associated with TACE is thought to be mediated via an increase in the amount of chemotherapeutic agent delivered to the tumor mass with less systemic toxicity.[11] As a treatment modality, it is gaining popularity for several reasons some of which are prolonged waiting lists for liver transplantation with the low number of donors especially in this part of the world and the increased number of HCC detected on surveillance.

Our study is the first to describe results of TACE in the Middle East where HCC is a very important and relatively common disease. Our results showed that this procedure is effective in reducing the tumor burden in the majority of patients with relatively low complication rate. These results are comparable to previously published trials in Europe and Asia.[6],[9]

Complication rates in our study were also very comparable to other studies. The one patient who died had a large tumor that was very close to the capsule of the liver. Although not clearly documented by others, we have abandoned this form of intervention in patients with tumors close to the capsule. The patient who developed severe cytotoxic side effects was a patient who developed HCC 3 years after receiving kidney transplantation. He was on Cyclosporine and Mycophenolate mofetil. After about 3 weeks of supportive therapy with blood product transfusions and granulocyte stimulation factors, he had a complete recovery.

As anticipated, the patients who achieved a complete response were CLIP stage 1 or less (26.7%) and the majorities were Child-Pugh class A apart from one who was class B. In fact one of the patients who achieved a complete response is awaiting orthotropic liver transplantation. On the other hand, the majority of patients who showed no response had masses that were considerably large. Although not clearly documented by others, we have limited the size of tumors to be treated in the future to a maximum of 10 cm. In our experience tumors larger than 10 cm have a very small chance of having a significant response. This conforms to the recommendations of the Saudi Gastroenterology Association.[12] As proven in previous studies, the favorable outcome obtained in these patients was due to the optimum selection of patients for TACE.

 Conclusion



A favorable outcome was achieved in properly selected patients treated with TACE in Saudi Arabia.

References

1Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;13:271-85.
2Kingdom of Saudi Arabia ministry of health. National Cancer Registry (1997-1998). 2001.
3Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30.
4Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al . Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
5A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-5.
6Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al . Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Lancet 2002;359:1734-9.
7Miller AB, Hoogstraten B, Straaquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
8Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
9Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al . Randomized controlled trial of Transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
10Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42.
11Breedis C, Young G. The blood supply of neoplasm in liver. Am J Pathol 1954;30:969-77.
12Abdo AA, Karim HA, Al Fuhaid T, Sanai FM, Kabbani M, Al Jumah A, et al . Saudi Gastroenterology Association Guidelines for the diagnosis and management of hepatocellular carcinoma: Summary of recommendations. Ann Saudi Med 2006;26:261-5.